Stock listing
Hanover:8T8 TransMedics Group, Inc. Aktie
German listing (Hanover) of TransMedics Group, Inc. · home listing NASDAQ:TMDX
Follow TransMedics Group, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:TMDX
$85.25 USD -11.18 (-11.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:TMDX
- Day range
- $83.89 – $91.62 USDNov 20, 2026
- Volume
- 1.59M sharesNov 20, 2026
- Market cap
- $2.96B USDAt the close on Nov 20, 2026 · price × 34.73M shares outstanding
- 52-week range
- $60.11 – $156.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $75.62M USDMedian day 789,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TMDX · Home | $85.25 USD | -11.18 (-11.6%) | 1,587,314 | $91.62 | $91.62 | $83.89 | $96.43 | Close on Nov 20, 2026 |
| Frankfurt:8T8 | €83.34 EUR | -3.74 (-4.3%) | — | €84.30 | €84.30 | €83.34 | €87.08 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TMDX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $85.25 | -11.18 | -11.6% | $91.62 | $91.62 | $83.89 | 1,587,314 | |
| $96.43 | +2.52 | +2.7% | $93.89 | $98.78 | $93.52 | 1,073,665 | |
| $93.91 | +1.70 | +1.8% | $91.73 | $95.60 | $91.32 | 959,439 | |
| $92.21 | +0.83 | +0.9% | $90.60 | $92.99 | $89.50 | 564,120 | |
| $91.38 | -0.62 | -0.7% | $92.39 | $94.28 | $91.17 | 840,032 | |
| $92.00 | -0.01 | 0.0% | $91.65 | $96.46 | $91.19 | 1,052,710 | |
| $92.01 | +1.065 | +1.2% | $90.95 | $93.45 | $90.00 | 913,847 | |
| $90.95 | -2.845 | -3.0% | $93.50 | $97.55 | $89.49 | 1,626,329 | |
| $93.79 | +5.55 | +6.3% | $88.00 | $95.30 | $87.22 | 2,065,716 | |
| $88.24 | +19.26 | +27.9% | $79.12 | $88.44 | $76.50 | 3,951,400 | |
| $68.98 | -3.775 | -5.2% | $72.49 | $73.61 | $67.33 | 1,692,300 | |
| $72.76 | +5.415 | +8.0% | $69.97 | $74.67 | $68.67 | 2,471,100 | |
| $67.34 | +0.67 | +1.0% | $66.90 | $68.82 | $66.36 | 704,700 | |
| $66.67 | +0.68 | +1.0% | $66.47 | $68.66 | $65.84 | 689,500 | |
| $65.99 | -1.13 | -1.7% | $67.59 | $67.75 | $64.64 | 898,500 | |
| $67.12 | +0.22 | +0.3% | $67.09 | $69.02 | $65.52 | 990,900 | |
| $66.90 | -2.83 | -4.1% | $69.02 | $69.98 | $66.68 | 1,180,500 | |
| $69.73 | -0.90 | -1.3% | $70.53 | $71.18 | $69.63 | 826,400 | |
| $70.63 | -0.11 | -0.2% | $70.01 | $71.97 | $69.61 | 847,600 | |
| $70.74 | -1.32 | -1.8% | $71.42 | $72.68 | $69.76 | 789,700 | |
| $72.06 | -0.34 | -0.5% | $72.34 | $73.66 | $70.52 | 627,700 | |
| $72.40 | -2.35 | -3.1% | $74.47 | $76.00 | $72.26 | 685,500 | |
| $74.75 | +3.15 | +4.4% | $71.65 | $75.66 | $67.31 | 1,172,800 | |
| $71.60 | +0.82 | +1.2% | $71.16 | $72.81 | $70.50 | 656,800 | |
| $70.78 | -5.74 | -7.5% | $76.52 | $76.52 | $70.03 | 1,068,000 | |
| $76.52 | +1.00 | +1.3% | $74.41 | $77.34 | $74.41 | 1,132,500 | |
| $75.52 | -3.615 | -4.6% | $78.20 | $78.36 | $74.84 | 891,400 | |
| $79.14 | +0.965 | +1.2% | $78.17 | $80.42 | $77.86 | 1,025,900 | |
| $78.17 | +0.30 | +0.4% | $77.69 | $78.50 | $77.14 | 491,700 | |
| $77.87 | -1.13 | -1.4% | $79.13 | $81.35 | $76.86 | 733,700 | |
| $79.00 | -2.07 | -2.6% | $80.25 | $80.28 | $77.50 | 949,400 | |
| $81.07 | +0.79 | +1.0% | $80.96 | $83.90 | $80.56 | 962,600 | |
| $80.28 | -2.71 | -3.3% | $83.87 | $84.05 | $80.08 | 570,700 | |
| $82.99 | +3.195 | +4.0% | $79.50 | $83.40 | $77.37 | 994,900 | |
| $79.80 | +1.155 | +1.5% | $79.81 | $80.85 | $77.14 | 1,223,300 | |
| $78.64 | -4.81 | -5.8% | $83.92 | $84.24 | $78.02 | 880,100 | |
| $83.45 | -0.62 | -0.7% | $84.87 | $84.87 | $81.55 | 566,600 | |
| $84.07 | +1.34 | +1.6% | $82.56 | $84.22 | $81.76 | 440,200 | |
| $82.73 | -2.56 | -3.0% | $86.38 | $86.38 | $82.70 | 422,500 | |
| $85.29 | +1.39 | +1.7% | $83.50 | $85.69 | $81.80 | 696,700 | |
| $83.90 | -3.10 | -3.6% | $86.09 | $86.09 | $82.53 | 623,700 | |
| $87.00 | -1.07 | -1.2% | $88.22 | $89.19 | $85.07 | 615,600 | |
| $88.07 | +0.78 | +0.9% | $88.15 | $89.80 | $86.50 | 750,700 | |
| $87.29 | +0.87 | +1.0% | $87.35 | $89.53 | $86.75 | 590,800 | |
| $86.42 | -0.24 | -0.3% | $87.18 | $87.98 | $85.01 | 1,441,700 | |
| $86.66 | -0.90 | -1.0% | $88.00 | $89.41 | $85.47 | 690,600 | |
| $87.56 | -0.53 | -0.6% | $88.17 | $88.28 | $86.29 | 464,700 | |
| $88.09 | +2.23 | +2.6% | $86.39 | $90.67 | $85.47 | 942,800 | |
| $85.86 | +3.68 | +4.5% | $82.62 | $88.49 | $80.59 | 942,900 | |
| $82.18 | -2.86 | -3.4% | $85.36 | $86.00 | $79.23 | 1,247,000 | |
| $85.04 | -1.36 | -1.6% | $85.27 | $87.55 | $83.69 | 590,900 | |
| $86.40 | -1.87 | -2.1% | $87.47 | $87.71 | $84.87 | 665,100 | |
| $88.27 | -1.71 | -1.9% | $89.14 | $89.55 | $86.15 | 594,500 | |
| $89.98 | +3.00 | +3.4% | $84.63 | $90.11 | $83.61 | 542,600 | |
| $86.98 | +2.69 | +3.2% | $85.72 | $87.55 | $84.60 | 574,800 | |
| $84.29 | +2.05 | +2.5% | $82.23 | $85.52 | $82.23 | 589,600 | |
| $82.24 | -2.63 | -3.1% | $85.84 | $86.00 | $81.34 | 883,900 | |
| $84.87 | -3.56 | -4.0% | $87.65 | $88.00 | $82.55 | 1,184,100 | |
| $88.43 | -3.32 | -3.6% | $91.90 | $93.45 | $88.37 | 630,900 | |
| $91.75 | -0.47 | -0.5% | $91.59 | $94.24 | $91.13 | 417,800 | |
| $92.22 | -1.38 | -1.5% | $92.26 | $93.16 | $90.24 | 448,800 | |
| $93.60 | 0.00 | 0.0% | $93.62 | $94.33 | $91.50 | 405,438 | |
| $93.60 | -1.17 | -1.2% | $94.07 | $94.52 | $92.04 | 770,374 | |
| $94.77 | +3.92 | +4.3% | $91.11 | $95.18 | $90.45 | 627,100 | |
| $90.85 | -3.12 | -3.3% | $92.88 | $94.30 | $90.64 | 589,300 |
- Ticker
- Hanover:8T8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
TransMedics Reports Third Quarter 2026 Financial Results
Latest earnings call · Nov 5, 2026
TransMedics Group (NASDAQ:TMDX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Baird 2026 Global Healthcare Conference
Conference · 14 slides
Latest news
TransMedics Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $88.24 (+27.9%) on Nov 6, 2026
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 30, 2026
Closed $66.67 (+1.0%) on Nov 2, 2026
TransMedics to Present at Upcoming Investor Conferences
Oct 29, 2026
Closed $65.99 (-1.7%) on Oct 30, 2026
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
Oct 22, 2026
Closed $70.74 (-1.8%) on Oct 23, 2026
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
Sep 10, 2026
Closed $82.18 (-3.4%) on Sep 11, 2026
TransMedics Reports Second Quarter 2026 Financial Results
Aug 4, 2026
Closed $76.49 (-5.3%) on Aug 5, 2026
TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
Jul 28, 2026
Closed $78.00 (+2.2%) on Jul 29, 2026
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
Jul 21, 2026
Closed $71.20 (-4.2%) on Jul 22, 2026
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
Jul 6, 2026
Closed $71.23 (+3.4%) on Jul 6, 2026
Normothermic Machine Perfusion Market is Going to Booming Growth 2026-2033 | TransMedics Group Inc, OrganOx Limited
May 7, 2026
Closed $72.90 (0.0%) on May 7, 2026
TransMedics Group, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 22 in the last 12 months · 139 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 24 calls with a replay · 24 with a transcript · latest Nov 5, 2026
- Decks
- 7 decks · latest September 2026
Where TransMedics Group, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TMDX · Home listing | NASDAQ | United States | USD |
| gettex:8T8 | gettex | Germany | EUR |
| BMV:TMDX | BMV | Mexico | MXN |
| LS Exchange:A2PH5P | LS Exchange | Germany | EUR |
| Tradegate:8T8 | Tradegate | Germany | EUR |
| Lang & Schwarz:A2PH5P | Lang & Schwarz | Germany | EUR |
| BOATS:TMDX | BOATS | United States | USD |
| Milan:1TMDX | Milan | Italy | EUR |
| BIVA:TMDX | BIVA | Mexico | MXN |
| BX Swiss:TMDX | BX Swiss | Switzerland | CHF |
| Frankfurt:8T8 | Frankfurt | Germany | EUR |
| Hamburg:8T8 | Hamburg | Germany | EUR |
| Stuttgart:8T8 | Stuttgart | Germany | EUR |
| Dusseldorf:8T8 | Dusseldorf | Germany | EUR |
| Munich:8T8 | Munich | Germany | EUR |
| Hanover:8T8 · This page | Hanover | Germany | EUR |
| Xetra:8T8 | Xetra | Germany | EUR |
Valuation
P/E 20.5× against a median of 31.2×: the lowest of 7 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.52B USD
- P/E
- 20.5×
- EV/sales
- 3.5×
- EV/EBITDA
- 19.8×
- Price/book
- 5.4×
- Gross margin
- 58.6%
- Operating margin
- 11.9%
- Net margin
- 19.9%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.31
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TransMedics Group, Inc. · NASDAQ:TMDX | US$2.96B | US$2.52B | 20.5× | 3.5× | 19.8× | 5.4× | 19.9% | 0.1× | 1.31 |
| Pulse Biosciences, Inc · NASDAQ:PLSE | US$3.35B | US$3.17B | n/a | 2,120× | n/a | 18.3× | n/a | 0.0× | 1.54 |
| Axogen, Inc. · NASDAQ:AXGN | US$3.33B | US$2.98B | n/a | 11.2× | n/a | 6.7× | −12.0% | 0.0× | 0.98 |
| Zhende Medical Co., Ltd. Class A · SSE:603301 | US$3.23B | US$3.13B | 73.1× | 4.5× | n/a | 3.8× | 6.3% | 0.1× | n/a |
| Lepu Medical Technology (Beijing) Co., Ltd. Class A · SZSE:300003 | US$3.10B | US$3.03B | 31.4× | 3.3× | n/a | 1.3× | 10.7% | 0.2× | n/a |
| Carl Zeiss Meditec AG · XETR:AFX | US$3.06B | US$3.06B | 23.9× | 1.1× | n/a | 1.3× | 4.4% | 0.0× | n/a |
| Imricor Medical Systems, Inc. · ASX:IMR | US$3.00B | US$2.96B | n/a | 9,794× | n/a | 103× | n/a | 1.2× | n/a |
| Ambu A/S Class B · OMXCOP:AMBU_B | US$2.92B | US$2.92B | 30.9× | 3.1× | 15.9× | 3.2× | 9.9% | 0.1× | n/a |
| AtriCure, Inc. · NASDAQ:ATRC | US$2.82B | US$2.69B | 190× | 4.6× | 75.2× | 5.3× | 2.5% | 0.1× | 0.58 |
| Shanghai MicroPort MedBot (Group) Co., Ltd. Class H · HKEX:2252 | US$2.77B | US$2.74B | n/a | 33.1× | n/a | 44.9× | −45.3% | 1.0× | n/a |
| Ottobock SE & Co. KGaA · XETR:OBCK | US$2.65B | US$3.54B | 26.8× | 1.9× | 8.0× | 6.1× | 5.4% | 2.3× | n/a |
| Median of the others | US$3.03B | US$3.01B | 31.2× | 4.5× | 15.9× | 5.7× | 4.9% | 0.1× | 0.98 |
Forecasts
6 strong buy · 3 buy · 4 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 105.45 USD · Analysts' mean
- EPS, year to Dec 2026
- 1.67 · 10 analysts
- Revenue, year to Dec 2026
- 767.1M · 12 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Waleed Hassanein | President and Chief Executive Officer |
| Fernando Araujo | Chief Financial Officer and Reiterates 2026 Financial Outlook |
| Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary |
| Miriam Provost | Vice President of Global Regulatory Affairs |
| Nick Corcoran | Senior Vice President of Supply Chain & Operations |
| Tamer Khayal | Chief Commercial Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| TransMedics Group (NASDAQ:TMDX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q2 2025 Earnings Call | Wed, Jul 30, 2025 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q3 2024 Earnings Call | Mon, Oct 28, 2024 · 4:30 PM ET | Replay |
| TransMedics Group (NASDAQ:TMDX) Q2 2024 Earnings Call | Wed, Jul 31, 2024 · 4:30 PM ET | Replay |
All 24 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +27.9% |
| Q2 2026 | Aug 4, 2026 · After close | −5.3% |
| Q1 2026 | May 5, 2026 · After close | −23.2% |
| Q4 2025 | Feb 24, 2026 | −2.1% |
| Q3 2025 | Oct 29, 2025 · After close | +1.1% |
| Q2 2025 | Jul 30, 2025 · After close | +10.5% |
| Q1 2025 | May 8, 2025 · After close | +19.6% |
| Q4 2024 | Feb 24, 2025 · After close | −5.3% |
| Q3 2024 | Oct 28, 2024 · After close | −29.9% |
| Q2 2024 | Jul 31, 2024 · After close | +6.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 30, 2024 · After close | +24.9% |
| Q4 2023 | Feb 26, 2024 · After close | +14.1% |
| Q3 2023 | Nov 6, 2023 · After close | +51.2% |
| Q2 2023 | Aug 3, 2023 · After close | −8.3% |
| Q1 2023 | May 1, 2023 · After close | −5.2% |
| Q4 2022 | Feb 22, 2023 · After close | +20.6% |
| Q3 2022 | Nov 3, 2022 · After close | +24.0% |
| Q2 2022 | Aug 1, 2022 · After close | −10.3% |
| Q1 2022 | May 3, 2022 · After close | +40.3% |
| Q4 2021 | Feb 23, 2022 · After close | +30.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Baird 2026 Global Healthcare Conference | Conference | 14 slides | September 2026 |
| Q2 2026 Earnings Presentation | Earnings | 14 slides | Aug 4, 2026 |
| William Blair 2026 | Conference | 21 slides | June 2026 |
| Q1 2026 Earnings Presentation | Earnings | 14 slides | May 5, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 9 slides | Feb 24, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 9 slides | Oct 29, 2025 |
| Investor Presentation (January 2020) | Investor deck | 24 slides | Jan 13, 2020 |
IPO
Priced at US$16.00 a share on May 1, 2019.
- Price
- US$16.00 a share
- Shares offered
- 5,690,000 shares of common stock
- Offering size
- US$91 million
- Underwriters' option
- Up to 853,500 more shares
- Underwriters
- MORGAN STANLEY, J.P. MORGAN, COWEN, CANACCORD GENUITY · In the order on the cover
- Shares delivered
- On or about May 6, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 19, 2018 |
| Filed publicly | Apr 5, 2019 |
| Amended 3 times | Newest May 1, 2019 |
| Shares registered with an exchange | May 1, 2019 |
| Declared effective by the SEC | May 1, 2019 |
| Final prospectus, with the price | May 2, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 2, 2019 |
| CERT · Exchange's certificate of listing | May 2, 2019 |
| EFFECT · Notice that a registration is effective | May 1, 2019 |
| S-1MEF · Registration of more shares for the same offering | May 1, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | May 1, 2019 |
| S-1/A · Registration statement, amended | May 1, 2019 |
| S-1/A · Registration statement, amended | Apr 30, 2019 |
| CORRESP · Letter to the SEC | Apr 29, 2019 |
| CORRESP · Letter to the SEC | Apr 29, 2019 |
| CORRESP · Letter to the SEC | Apr 29, 2019 |
All 21 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Apr 22, 2019 |
| S-1/A · Registration statement, amended | Apr 22, 2019 |
| UPLOAD · Letter from the SEC | Apr 18, 2019 |
| CORRESP · Letter to the SEC | Apr 16, 2019 |
| CORRESP · Letter to the SEC | Apr 10, 2019 |
| S-1 · Registration statement | Apr 5, 2019 |
| DRS/A · Draft registration statement, amended | Mar 29, 2019 |
| DRSLTR · Letter to the SEC with a draft | Dec 12, 2018 |
| DRS/A · Draft registration statement, amended | Dec 12, 2018 |
| UPLOAD · Letter from the SEC | Nov 16, 2018 |
| DRS · Draft registration statement | Oct 19, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed May 2, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 605.5M | 441.5M | 241.6M | 93.5M | 30.3M | 25.6M | 23.6M | 13.0M | 7.68M | 6.21M |
| Cost of revenue | 242.7M | 179.5M | 87.5M | 28.2M | 9.10M | 9.00M | 9.74M | 7.28M | 5.55M | 5.44M |
| Gross profit | 362.8M | 262.1M | 154.1M | 65.3M | 21.2M | 16.6M | 13.9M | 5.73M | 2.14M | 766.0K |
| Research and development | 69.1M | 56.0M | 36.1M | 26.8M | 22.3M | 18.8M | 19.9M | 13.7M | 15.0M | 15.6M |
| Selling, general and administrative | 185.2M | 168.6M | 119.6M | 69.9M | 38.3M | 24.2M | 23.6M | 12.3M | 7.61M | 8.12M |
| Operating income | 108.6M | 37.5M | -28.7M | -31.4M | -39.4M | -26.4M | -29.6M | -20.2M | -20.4M | -23.0M |
| Depreciation and amortization | 27.2M | 19.8M | 8.18M | 3.48M | 1.82M | 1.58M | 1.22M | 769.0K | 630.0K | 426.0K |
| EBITDA | 135.8M | 57.3M | -20.6M | -28.0M | -37.6M | -24.8M | -28.4M | -19.5M | -19.8M | -22.6M |
| Interest expense | 13.8M | 14.4M | 10.8M | 3.73M | 3.87M | 3.98M | 4.35M | 2.72M | 1.07M | 979.0K |
| Income before tax | 107.5M | 35.8M | -26.7M | -36.2M | -44.2M | -28.7M | -33.5M | -23.7M | -20.8M | -24.1M |
| Income tax | -82.8M | 316.0K | -1.64M | 66.0K | 36.0K | 0 | 0 | 0 | 0 | 984.0K |
| Net income | 190.3M | 35.5M | -25.0M | -36.2M | -44.2M | -28.7M | -33.5M | -23.8M | -20.8M | -24.1M |
| Earnings per share, basic | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -17.48 | -0.98 | -1.66 |
| Earnings per share, diluted | 4.87 | 1.01 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -17.48 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 488.4M | 336.6M | 394.8M | 201.2M | 25.6M | 24.6M | 20.1M | 20.2M | 12.4M | 9.84M |
| Short-term investments | 0 | 66.9M | 101.1M | 60.6M | 0 | 12.7M | 38.0M | |||
| Receivables | 84.3M | 97.7M | 63.6M | 27.6M | 5.93M | 6.86M | 6.56M | 3.44M | 925.0K | 1.38M |
| Inventory | 48.9M | 46.6M | 44.2M | 20.6M | 14.9M | 11.9M | 11.2M | 9.28M | 7.97M | 6.33M |
| Current assets | 637.8M | 497.2M | 510.7M | 252.3M | 118.7M | 146.8M | 100.0M | 34.8M | 34.0M | 55.9M |
| Property, plant and equipment | 327.7M | 286.0M | 173.9M | 19.2M | 9.84M | 4.75M | 4.79M | 3.47M | 2.46M | 1.72M |
| Goodwill | 11.5M | 11.5M | 12.0M | 0 | ||||||
| Total assets | 1.07B | 804.1M | 706.0M | 277.1M | 134.9M | 152.0M | 105.3M | 42.2M | 37.0M | 58.1M |
| Accounts payable | 10.3M | 10.3M | 12.7M | 3.34M | 6.65M | 1.21M | 7.25M | 4.72M | 3.52M | 4.25M |
| Current liabilities | 89.3M | 59.9M | 54.9M | 23.7M | 23.2M | 11.9M | 16.1M | 12.6M | 10.9M | 9.47M |
| Long-term debt | 502.4M | 509.3M | 506.2M | 58.7M | 35.2M | 34.7M | 34.1M | 33.7M | 6.85M | 8.41M |
| Total debt | 10.0M | 518.3M | 515.9M | 58.7M | 35.2M | 34.7M | 34.1M | 33.7M | 8.65M | 8.41M |
| Total liabilities | 595.3M | 575.5M | 568.8M | 89.8M | 67.0M | 48.1M | 50.6M | 47.9M | 205.7M | 19.3M |
| Shareholders' equity | 473.1M | 228.6M | 137.2M | 187.4M | 67.9M | 103.9M | 54.6M | -192.2M | -168.7M | 38.8M |
| Shares outstanding | 34.3M | 33.6M | 32.7M | 32.1M | 27.8M | 27.2M | 21.2M | 1.40M | 21.2M | 14.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 192.8M | 48.8M | -13.0M | -45.8M | -28.9M | -30.3M | -32.3M | -26.0M | -23.1M | -24.1M |
| Capital spending | -59.3M | -129.7M | -151.8M | -11.9M | -3.52M | -455.0K | -165.0K | -418.0K | -263.0K | -1.48M |
| Free cash flow | 133.6M | -80.9M | -164.9M | -57.7M | -32.4M | -30.7M | -32.5M | -26.4M | -23.4M | -25.6M |
| Cash from investing | -59.3M | -129.3M | -194.0M | 54.5M | 29.3M | -41.6M | -60.5M | 12.3M | 24.9M | -39.7M |
| Cash from financing | 16.9M | 22.9M | 400.4M | 167.9M | 1.39M | 75.5M | 92.7M | 22.1M | 3.00K | 63.5M |
| Dividends paid | -51.1M | -357.0K | ||||||||
| Share buybacks | -138.0K | 955.0K | 509.0K | 419.0K | 357.0K | 202.0K | 46.0K | 3.00K | 63.6M | |
| Change in cash | 151.7M | -58.2M | 193.6M | 175.6M | 999.0K | 4.49M | -149.0K | 8.30M | 2.10M | -243.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| SD · Specialized disclosure | May 29, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | May 7, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 10, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 27, 2026 | Results | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Feb 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 4, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 6, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 4, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 8-K · Current report | May 23, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 9, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2025 | Other filings | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 21, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Jan 14, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2024 | Acquisition or disposal | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 2, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 1, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 29, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Aug 1, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 31, 2024 | Results | SEC |
| 8-K · Current report | Jul 29, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2024 | Other filings | SEC |
| SD · Specialized disclosure | May 31, 2024 | ESG report | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 8-K · Current report | May 28, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 10, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 2, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 10, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 10, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 8, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 18, 2024 | Other filings | SEC |
This page holds 200 of 632 filings. Open Filings
Cap table
Built by 6ix from TransMedics Group, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 34,733,883
- Fully diluted
- 34,733,883
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 34,733,883 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 34,733,883 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Merilee Raines Other companies: Ocular Therapeutix, Inc. (Director · Since at least Sep 20, 2021); Watts Water Technologies, Inc. (Director · Since at least Feb 7, 2011); Benchmark Electronics, Inc. (Director · May 18, 2018 – May 12, 2021 · Past); Affymetrix Inc (Director · Jan 12, 2015 – Mar 31, 2016 · Past); Aratana Therapeutics Inc (Director · Feb 5, 2014 – Jul 18, 2019 · Past); IDEXX Laboratories, Inc. (Executive VP & CFO · Jan 13, 2006 – Feb 25, 2013 · Past) | Director · Since at least Jan 1, 2021 |
| Edwin M. Kania Other companies: Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – May 16, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Jan 8, 2015 · Past); EXACT Sciences Corporation (Director · Jul 21, 2006 – Jul 20, 2009 · Past) | Director · Since at least May 1, 2019 |
| James R. Tobin Other companies: Lyra Therapeutics, Inc. (Lead Independent Director · Since at least Mar 4, 2022); Globus Medical, Inc. (Director · Since at least Jan 14, 2021); Oxford Immunotec Global PLC (Director · Mar 8, 2021 – Mar 8, 2021 · Past) | Director · Since at least Feb 9, 2021 |
| Stephanie Lovell Other companies: Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Jun 14, 2022 · Past) | Director · Since at least Mar 22, 2021 |
| Thomas J. Gunderson Other companies: Merit Medical Systems, Inc. (Member, Compensation, Talent Development Committee, Finance, Operating Committee · Since at least May 24, 2017) | Director · Since at least May 1, 2019 |
| Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary · Since at least Jun 5, 2023 |
| David Weill | Director · Since at least May 1, 2019 |
| Edward M. Basile | Director · Since at least May 1, 2019 |
| Fernando Araujo | Chief Financial Officer and Reiterates 2026 Financial Outlook · Since at least Sep 10, 2026 |
| Gerardo Hernandez | Chief Financial Officer · Since at least Dec 2, 2024 |
All 24 people
| Person | Seat |
|---|---|
| Gerardo Hernandez Omana | Until Sep 10, 2026 · Past |
| Giovanni Cecere | Chief Commercial Officer · Since at least Mar 14, 2025 |
| James Gilbert | Director · May 1, 2019 – May 1, 2019 · Past |
| John F Carey | VP of Operations · May 1, 2019 – Feb 1, 2023 · Past |
| John F Sullivan | VP of Quality & Engineering · May 1, 2019 – Aug 30, 2021 · Past |
| Laura Damme | VP, Clinical Affairs · Aug 5, 2019 – Feb 20, 2023 · Past |
| Matthew S Forsyth | See Remarks · Since at least Mar 9, 2026 |
| Miriam Provost | Vice President of Global Regulatory Affairs · Since at least May 1, 2019 |
| Nicholas Corcoran | See remarks · Since at least Jan 23, 2023 |
| Nick Corcoran | Senior Vice President of Supply Chain & Operations · Since at least Jan 12, 2026 |
| Rakesh P Godhani | Chief Digital Officer · Aug 4, 2021 – Aug 4, 2021 · Past |
| Stephen Gordon | Chief Financial Officer · May 1, 2019 – Jun 3, 2024 · Past |
| Tamer Khayal | Chief Commercial Officer · Since at least May 1, 2019 |
| Waleed Hassanein | President and Chief Executive Officer · Since at least May 1, 2019 |
Log in to ask 6ix AI your own questions about TransMedics Group, Inc.